Silexion Therapeutics
SLXN
10 hedge funds and large institutions have $233K invested in Silexion Therapeutics in 2026 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
2,565% more capital inflows, than outflows
Capital inflows: $1.04M | Capital outflows: $38.9K
247.25% more ownership
Funds ownership: 5.18% → 252.44% (+247%)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
67% more funds holding
Funds holding: 6 → 10 (+4)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$648K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$278K |
| 3 |
Jane Street
New York
|
+$89.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$19.8K |
| 5 |
JP Morgan Chase
New York
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$38K |
| 2 |
Montag & Associates
Atlanta,
Georgia
|
-$765 |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$89 |
SLXN Hedge Fund Activity: Q3 2026 in Review
10 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2026, worth a combined $233K — up 443% from $42.8K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SLXN positions and 2 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $648K. The largest seller was HRT Financial, exiting entirely with an estimated $38K sold.
- 10 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2026, up from 6 in Q2 2026.
- Funds reported $233K of Silexion Therapeutics stock for Q3 2026, up 443% quarter-over-quarter.
- 6 funds opened new Silexion Therapeutics positions in Q3 2026 and 2 closed out, a net change of +4 holders.
- The largest Silexion Therapeutics buyer in Q3 2026 was Armistice Capital, an estimated $648K added.
- The largest Silexion Therapeutics seller in Q3 2026 was HRT Financial, an estimated $38K sold.
Based on aggregated 13F filings for Q3 2026.